BRAMPTON, Ontario, Oct. 26, 2025 (GLOBE NEWSWIRE) — With over 600 million people with disabilities globally facing unemployment rates between 70-90%, Enabled Talent officially launched its full-scale inclusive employment platform from Brampton's Innovation District, expanding internationally with a regional rollout in Africa. Founded by a partially blind entrepreneur and powered by the lived experience of […]

Enabled Talent Launches from Brampton to Tap Into the World's Largest Untapped Workforce GlobeNewswire October 26, 2025 BRAMPTON, Ontario, Oct. 26, 2025 (GLOBE NEWSWIRE) — With over 600 million people with disabilities globally facing unemployment rates between 70-90%, Enabled Talent officially launched its full-scale inclusive employment platform from Brampton's Innovation District, expanding internationally with a

(NasdaqGM:CSTL), FRIENDSWOOD, Texas, Oct. 26, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating that its TissueCypher(R) Barrett's Esophagus test can provide risk insights beyond pathology alone, influencing clinical management to support earlier intervention for those at higher risk

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher(R) Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett's Esophagus Research on TissueCypher by Horvath et al. honored with a Presidential Poster Award from the ACG Abstract Selection Committee, a distinction awarded to only 5-7% of abstracts for research

CESSA Phase 3 Clinical Trial Results Earn ACG Presidential Poster Distinction Among Nearly 6,000 Abstracts Next-generation Hydrocortisone Acetate (ngHCA™) Suppository Administered with Sephure® Suppository Applicator Demonstrates Statistically Significant Rates of Clinical Remission in Patients with UC in CESSA Phase 3 Trial Additional Findings Reinforce Rapid and Sustained Drug Release of ngHCA Cristcot, a clinical-stage pharmaceutical

— SELUTION DeNovo Trial – the largest randomized Drug Eluting Balloon trial – demonstrates a SELUTION SLR™ DEB strategy is non-inferior to a Drug Eluting Stent treatment strategy in de novo lesions. — SELUTION4ISR, a randomized controlled trial, provesSELUTION SLR™ DEB is an alternative to current standard of care for In-Stent Restenosis (ISR) treatment. Cordis,

(NASDAQ:MRX), NEW YORK, Oct. 26, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline. SO WHAT: If

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Marex Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRX GlobeNewswire October 26, 2025 NEW YORK, Oct. 26, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX) between May

Newly uncovered DEA agreements confirm what MMJ BioPharma Cultivation has argued for years – that the agency’s own rules make it impossible for any company to legally produce pharmaceutical grade cannabis for FDA authorized clinical research. WASHINGTON, D.C. / ACCESS Newswire / October 26, 2025 / A recently disclosed memorandum of understanding between the DEA

Photo courtesy of Inex Club LIMASSOL, Cyprus, Oct. 26, 2025 (GLOBE NEWSWIRE) — Following the resounding success of last year's ARETI Gran Prix Cyprus 2024, which brought together more than 150 cyclists and created an unforgettable atmosphere of sporting celebration, ARETI International Group is proud to announce its continued support as a sponsor of the